Personalizing Healthcare Through Data With General Genomics

https://www.dnaweekly.com/blog/general-genomics-interview/

Published on May 21, 2021 by Ditsa Keren – DNA Weekly (https://www.dnaweekly.com)

General Genomics is a bioinformatics artificial intelligence platform that provides customers with a comprehensive analysis of disease susceptibility and treatment effectiveness. In this interview, co-founders AJ Rosenthal and Warren Gieck discuss the importance of medical data ownership and its anticipated impact on personalized and preventative healthcare.

Please describe the story behind the company: What sparked the idea, and how has it evolved so far?

AJ: We started General Genomics right as the pandemic kicked off, around March of 2020. Schools were shut down, so I had my son with me, and he was asking some questions about Coronavirus and whether or not we would get sick or die. He was clearly upset and frightened, so I promised I would figure it out and called Warren, my old colleague from General Electric.

At the time, Warren was working in the artificial intelligence sphere at the center of innovation in Calgary, Alberta, where we first met. I called him up and told him about my idea, which seemed crazy at the time, to apply machine learning algorithms and put them into something that would solve the world’s problems. Surprisingly, we came to realize that no one has done it before. We had a scratch-your-head moment, and the next thing we knew it, we were getting these patents registered and starting our journey as a company.

Warren: AJ and I have known each other for quite a few years. We used to work at General Electric together. I led artificial intelligence and machine learning projects across different industries and verticals, including aviation, oil and gas, and healthcare.

In aviation, they process a terabyte of data every time a plane comes off the ground. We are used to processing vast amounts of data. We were able to work through DNA and medical datasets with surprising ease.

AJ: We are thought disruptors and innovators. We’re bringing ideas to market that nobody’s ever done before. Many people in the healthcare industry thought it was an impossible task because we weren’t directly from the healthcare industry. That actually gave us an advantage, both in terms of experience and know-how and in implementing solutions in a highly regulated industry that is swarmed with lobbyists and intermediaries with conflicting interests.

Because we come from an outside industry and expertise, our perspective is generally more holistic. We want a better place for our children and grandchildren to grow up in. That’s what General Genomics is all about.

What is the role of AI in healthcare?

Warren: Currently, the healthcare industry does not utilize even a fraction of their data. When you do a study, you’re intentionally only looking at one or two variables. For example, clinical studies will have a control group taking a placebo and a treatment group taking the actual drug. Even if you have thousands of participants, you’re not getting an accurate indication of why some people have side effects and don’t. The drug companies warn us that these side effects may occur, but there’s no correlation to why they would occur and who should be avoiding them. That’s essentially the challenge that we’re pursuing.

There’s a lot of data available now between genetics, wearable devices, and health analytics. People record so much data about their health and wellness. Somewhere in that data are the answers to those questions.

COVID is an excellent example where some people have severe or long-term reactions, while others show no symptoms at all. The potential correlations could be medications and supplements, or they could be age, race, and sex. When you bring machine learning into outlying areas of health care, such as mapping the genome, you begin to reveal the complex multi-dimensional relationships that determine one’s susceptibility to diseases and the effectiveness of treatments on their body.

All of those factors are important, but when you’re just looking at one or two variables, you only get a tiny piece of the potential correlation. For example, I have high blood pressure. Doctors call it Primary Hypertension, which means they have no idea what’s causing it. They’ve tried all sorts of drugs, and some of them actually increased my blood pressure, and they still don’t know why I have it.

The answer is somewhere in the data. It may be that we’re not collecting the right data at this point; maybe it’s not about genetics and is more to do with lifestyle. As we add more and more data, we’re able to get a clearer understanding and hopefully provide better treatments to individuals.

I think data needs to play a bigger role in healthcare, and we even hear that from doctors. We are working with a very influential Doctor who specializes in head trauma. One of his biggest concerns right now is the opioid crisis.

When a doctor like him has to prescribe painkillers, because their patient had a major accident, they don’t usually know which drugs would work best for that specific patient. They start with one drug, and if it doesn’t work, they try the next one, and the next one, and so on. During this trial and error, the prescribing doctor just hopes that it doesn’t harm them or get them addicted. Thankfully, we’re starting to see an increased use of data across the industry, and General Genomics is certainly at the forefront of that.

AJ: We have two registered patents that we filed in April of 2020. One is around susceptibility to disease and the other is about survivability from both disease and treatments.

Our susceptibility algorithm applies to all living organisms on the planet, humans and animals alike. That rolls into swine flu, avian flu, hoof and mouth disease, cattle string, etc.

Our second patent uses genetic data and predictive analytics to determine the degree of survivability with different treatment strategies.

We recently gave a talk to a group of doctors. They understood how artificial intellegence and machine learning would help them diagnose and prescribe medication, but they couldn’t understand the mechanism because the way they are taught in school is a lot more qualitative than quantitative. It’s a yes/no mechanism. Did the treatment work or not? Were there side effects or not?

When you start mapping it out genetically and environmentally, person by person, you see that even though we’re all made of the same building blocks, each one of us is unique. Therefore it makes sense that certain treatments will work for us and others won’t.

But General Genomics isn’t just about diseases. We know that people who live in certain environments are exposed to environmental contaminants. People who live by a power plant or large electrical wires might be faced with increased electromagnetic radiation. Over time, their body may become susceptible to it.

All those correlating factors produce predictive models. Our engineer-style approach to medicine breaks down the body into parts, just like an electromechanical system. If your heart is a pump and the synapses in your nervous system is the electrical system, your body is essentially a biomechanical system. With the right data, we can optimize our health at much greater efficiency than ever before.

General Genomics Interview

What do you think is required to make personalized health data more available to the general public?

As data becomes more and more available, doctors, like engineers, are searching for more scientific approaches that are backed by confirmed scientific data so they have better confidence in the treatment plans they offer to patients. This is where solutions like ours come into play. We’re certainly seeing that as we enable more of these tools, doctors themselves also change some of their strategies.

One of our driving forces is to give individuals the ability to control their own health and medical information. Right now, you typically don’t get to see your test results. If you do keep a copy of them, you might see a summary sheet, but you won’t get a copy of the raw data. That is your data!

You might be moving between states, provinces, and countries, or you might want to give your data to children, a research institute, or a different medical practice. Those are all examples highlighting the necessity to transfer medical data.

Since it’s your personal data, we believe you should be in control of it, but typically, only another doctor or physician can get the data. A lot of dentists nowadays are looking for things like your latest blood panels, scans, or information, but they don’t have access to those medical systems so they have to request it through the patient.

Individuals need to take more responsibility and ownership of their health and health data. Our database is fully anonymized, so even if somebody were to break the encryption levels, they wouldn’t be able to connect the person and the data. With that kind of security control, people could have exclusive access to their data and decide who they want to share it with.

How do you envision the future of healthcare?

Warren: I think the future of healthcare lies in solutions that will help both doctors and patients get a more comprehensive picture of potential side effects in response to a treatment or an illness, so they can make better, more informed health decisions.

Personalized medicine and telemedicine are becoming increasingly prevalent. Making that knowledge more available to professionals and individual patients is where healthcare needs to go.

Most people aren’t aware that healthcare is the number one expense in almost any government’s budget, outweighing education, military, and social welfare. Optimizing our health care system to be more efficient with data could greatly impact our economies. It’s not just about the health of individuals, but about public health as a whole, both physical and mental.

We are seeing more holistic approaches with a lot of practices in Canada and the US. More and more clinics are starting to have a variety of medical and health resources. Certainly, alternative medicines and healers are gaining recognition and more and more people are using them, searching for more personalized and preventative medicine.

Functional medicine has increased dramatically. Supplements, vitamins, and preventative diets have been trending. For example, during the pandemic, there has been a lot of information on the importance of zinc, vitamin D, and other preventative supplements. Doctors are certainly not ignoring it, but change takes time. I think it’s going to trend more and more that way but it’s really up to the individual to take control of their own health and wellness. It’s to do with the patient choosing their own path or helping to educate their doctors

Of course, there are certain areas where hospitals and doctors don’t necessarily need personalization, like trauma, broken bones, accidents, or heart attacks. So I think the change has to happen at the family practitioner level.

I look at the pandemic and the decisions that go back and forth every day. They have just as many doctors on one side as they do on the other; they cannot reach a consensus, and the discussions around it have become almost political. From our perspective, if you remove the interpretations out of the equation, you’ve already done a lot. At General Genomics, we take an agnostic, engineerial approach. We’re not here to choose sides. We just want to provide doctors with better tools so they can utilize data more effectively.  Solutions like ours help reveal that nothing is absolute, and that nature is wild and far more complex than we think. Using AI, we can create the tools for a new type of medicine that is far more accurate than we ever imagined.

Article: Could a blood test predict whether coronavirus will kill you? Researchers find five signs for inflammation and blood vessel problems that could tell doctors which COVID-19 patients are at risk for fatal infection

  • Researchers at George Washington University tested the blood of 299 COVID-19 patients hospitalized at the school’s facility 
  • Of those, 200 had all five biomarkers linked to inflammation and blood vessel problems 
  • Higher levels of any or all of the biomarkers were linked to greater risks of ICU admission or needing to be put on a mechanical ventilator 
  • Patients with levels the highest levels of two of the five biomarkers were at greatest risk of death, suggesting blood tests could indicate who gets sickest 

By NATALIE RAHHAL ACTING US HEALTH EDITOR

PUBLISHED: 19:22 EST, 11 August 2020 | UPDATED: 10:41 EST, 12 August 2020

Researchers at George Washington University (GWU) believe that a simple blood test could predict which coronavirus patients could become deathly ill. 

The scientists have identified five biomarkers that indicate risks of complications like inflammation and bleeding disorders that make someone more likely to die if they contract coronavirus. 

High levels of two of these blood indicators, in particular, are linked to far greater odds of dying from the infection. 

The GWU team believes a blood test for these biomarkers could give doctors a clearer picture of who might need ventilator support or early aggressive treatment with a more finely tuned tool than general risk factors like age and underlying conditions. 

A blood test for five biomarkers of inflammation and blood vessel malfunctions could help doctors predict which coronavirus patients are at greatest risk of death, a new study suggests

People over the age of 65 and those with underlying conditions are typically less able to fight off any infection, not just COVID-19. 

But coronavirus has proven deadly to scores of otherwise healthy, relatively young people too – and scientists are still not sure exactly why some COVID-19 patients quickly spiral downward and others have no symptoms at all. 

And knowing who might need the most aggressive care is critical for hospitals when the threat of drug and supply shortages looms. 

New York City narrowly avoided a shortage of ventilators when it became the global epicenter of the pandemic in March and April. 

Several hospitals in hard-hit parts of Texas completely ran out of beds for coronavirus patients (or others) as cases spiked there in June and July. 

Even though Texas and other sunbelt states are seeing fewer new cases per day, hospitalization rates remain high. Florida reported a new record high number of coronavirus deaths in a single day on Tuesday and cases continue to climb in states like Georgia, Alabama, Illinois and Illinois. 

And nationwide, there are still shortages of drugs needed for patients on mechanical ventilators and of the only FDA-authorized treatment, remdesivir. 

Treating any and all patients sick enough to need to be hospitalized as early as possible is the best course of action – but it’s also a luxury doctors may not have the needed supplies are so precious. 

Grim though it may sound, health care providers may have to choose for one patient to get treatment over another – and a blood test could make these decisions both easier and more likely to be the correct ones. 

‘When we first started treating COVID-19 patients, we watched them get better or get worse, but we didn’t know why,’ said Dr Juan Reyes, study co-author and assistant professor at GW School of Medicine.

‘Some initial studies had come out of China showing certain biomarkers were associated with bad outcomes. There was a desire to see if that was true for our patients here in the US.’ 

The data that Dr Reyes and his colleagues saw out of China inspired them to assess the blood levels of five biomarkers in COVID-19 patients at GW Hospital. 

The biomarkers they looked at were: 

  • IL-6, which is short for interleukin 6, one of several cytokine immune cells that raises the alarm to other parts of the immune cell and can indicate out of control inflammation. 
  • D-dimers, which are bits of degraded protein detectable in the blood after a clot disintegrates, and signal that the virus may be attacking blood vessels. 
  • CRP, or C-reactive protein, which is released by the liver in response to inflammation. 
  • LDH, or Lactate Dehydrogenase, an enzyme in lactic acid that the body sends to heal damaged tissues. 
  • Ferritin, a protein that helps the body’s cells store iron. Iron in turn, is crucial for healthy red blood cells that carry oxygen throughout the body. Too much or too little ferritin can signal anemia or an infection that’s impairing blood cell function.     

Of the 299 COVID-19 patients whose blood they tested, the researchers found all five biomarkers in 200. 

Patients with higher levels any or all of these biomarkers were more likely to need to be treated in the ICU or put on ventilators. 

High LDH levels (greater than 1200 units/l) or high D-dimer levels (greater than 3 μg/ml) predicted the greatest risks that patients would die of coronavirus. 

‘We hope these biomarkers help physicians determine how aggressively they need to treat patients, whether a patient should be discharged, and how to monitor patients who are going home, among other clinical decisions,’ said Dr Shant Ayanian, an assistant professor and the study’s first author.

https://www.dailymail.co.uk/health/article-8617439/Could-blood-test-predict-coronavirus-kill-you.html

Article: The people with hidden immunity against Covid-19

While the latest research suggests that antibodies against Covid-19 could be lost in just three months, a new hope has appeared on the horizon: the enigmatic T cell.

By Zaria Gorvett

19th July 2020

(Image credit: Getty Images)

A scientist testing a Covid-19 vaccine on some cells (Credit: Getty Images)

The clues have been mounting for a while. First, scientists discovered patients who had recovered from infection with Covid-19, but mysteriously didn’t have any antibodies against it. Next it emerged that this might be the case for a significant number of people. Then came the finding that many of those who do develop antibodies seem to lose them again after just a few months.

In short, though antibodies have proved invaluable for tracking the spread of the pandemic, they might not have the leading role in immunity that we once thought. If we are going to acquire long-term protection, it looks increasingly like it might have to come from somewhere else.  

But while the world has been preoccupied with antibodies, researchers have started to realise that there might be another form of immunity – one which, in some cases, has been lurking undetected in the body for years. An enigmatic type of white blood cell is gaining prominence. And though it hasn’t previously featured heavily in the public consciousness, it may well prove to be crucial in our fight against Covid-19. This could be the T cell’s big moment.

When researchers tested blood samples taken years before the pandemic started, they found T cells which were specifically tailored to detect proteins on the surface of Covid-19

T cells are a kind of immune cell, whose main purpose is to identify and kill invading pathogens or infected cells. It does this using proteins on its surface, which can bind to proteins on the surface of these imposters. Each T cell is highly specific – there are trillions of possible versions of these surface proteins, which can each recognise a different target. Because T cells can hang around in the blood for years after an infection, they also contribute to the immune system’s “long-term memory” and allow it to mount a faster and more effective response when it’s exposed to an old foe.  

Several studies have shown that people infected with Covid-19 tend to have T cells that can target the virus, regardless of whether they have experienced symptoms. So far, so normal. But scientists have also recently discovered that some people can test negative for antibodies against Covid-19 and positive for T cells that can identify the virus. This has led to suspicions that some level of immunity against the disease might be twice as common as was previously thought.

Most bizarrely of all, when researchers tested blood samples taken years before the pandemic started, they found T cells which were specifically tailored to detect proteins on the surface of Covid-19. This suggests that some people already had a pre-existing degree of resistance against the virus before it ever infected a human. And it appears to be surprisingly prevalent: 40-60% of unexposed individuals had these cells.Aids is primarily a disease of T cells, which are systematically eliminated by HIV in patients who are infected by the virus (Credit: Martin Keene/PA)

Aids is primarily a disease of T cells, which are systematically eliminated by HIV in patients who are infected by the virus (Credit: Martin Keene/PA)

It looks increasingly like T cells might be a secret source of immunity to Covid-19.

The central role of T cells could also help to explain some of the quirks that have so far eluded understanding – from the dramatic escalation in risk that people face from the virus as they get older, to the mysterious discovery that it can destroy the spleen.

Deciphering the importance of T cells isn’t just a matter of academic curiosity. If scientists know which aspects of the immune system are the most important, they can direct their efforts to make vaccines and treatments that work.

How immunity unfolds

Most people probably haven’t thought about T cells, or T lymphocytes as they are also known, since school, but to see just how crucial they are for immunity, we can look to late-stage Aids. The persistent fevers. The sores. The fatigue. The weight loss. The rare cancers. The normally harmless microbes, such as the fungus Candida albicans – usually found on the skin – which start to take over the body.

Over the course of months or years, HIV enacts a kind of T cell genocide, in which it hunts them down, gets inside them and systematically makes them commit suicide. “It wipes out a large fraction of them,” says Adrian Hayday, an immunology professor at King’s College London and group leader at the Francis Crick Institute. “And so that really emphasises how incredibly important these cells are – and that antibodies alone are not going to get you through.”

During a normal immune response – to, let’s say, a flu virus – the first line of defence is the innate immune system, which involves white blood cells and chemical signals that raise the alarm. This initiates the production of antibodies, which kick in a few weeks later.

“And in parallel with that, starting out about four or five days after infection, you begin to see T cells getting activated, and indications they are specifically recognising cells infected with the virus,” says Hayday. These unlucky cells are then dispatched quickly and brutally – either directly by the T cells themselves, or by other parts of the immune system they recruit to do the unpleasant task for them – before the virus has a chance to turn them into factories that churn out more copies of itself. There's growing evidence that some people might have a hidden reservoir of protection from Covid-19 (Credit: Getty Images)

There’s growing evidence that some people might have a hidden reservoir of protection from Covid-19 (Credit: Getty Images)

The good and bad news

So, what do we know about T cells and Covid-19?

“Looking at Covid-19 patients – but also I’m happy to say, looking at individuals who have been infected but did not need hospitalisation – it’s absolutely clear that there are T cell responses,” says Hayday. “And almost certainly this is very good news for those who are interested in vaccines, because clearly we’re capable of making antibodies and making T cells that see the virus. That’s all good.”

In fact, one vaccine – developed by the University of Oxford – has already been shown to trigger the production of these cells, in addition to antibodies. It’s still too early to know how protective the response will be, but one member of the research group told BBC News that the results were “extremely promising”. (Read more about the Oxford University vaccine and what it’s like to be part of the trial).

There is a catch, however. In many patients who are hospitalised with more serious Covid-19, the T cell response hasn’t quite gone to plan.   

“Vast numbers of T cells are being affected,” says Hayday. “And what is happening to them is a bit like a wedding party or a stag night gone wrong – I mean massive amounts of activity and proliferation, but the cells are also just disappearing from the blood.”

One theory is that these T cells are just being redirected to where they’re needed most, such as the lungs. But his team suspects that a lot of them are dying instead.

“Autopsies of Covid-19 patients are beginning to reveal what we call necrosis, which is a sort of rotting,” he says. This is particularly evident in the areas of the spleen and lymph glands where T cells normally live.

Disconcertingly, spleen necrosis is a hallmark of T cell disease, in which the immune cells themselves are attacked. “If you look in post-mortems of Aids patients, you see these same problems,” says Hayday. “But HIV is a virus that directly infects T cells, it knocks on the door and it gets in.” In contrast, there is currently no evidence that the Covid-19 virus is able to do this.

“There are potentially many explanations for this, but to my knowledge, nobody has one yet,” says Hayday. “We have no idea what is happening. There’s every evidence that the T cells can protect you, probably for many years. But when people get ill, the rug seems to be being pulled from under them in their attempts to set up that protective defence mechanism.”T cells can lurk in the body for years after an infection is cleared, providing the immune system with a long-term memory (Credit: Reuters/Alkis Konstantinidis)

T cells can lurk in the body for years after an infection is cleared, providing the immune system with a long-term memory (Credit: Reuters/Alkis Konstantinidis)

Dwindling T cells might also be to blame for why the elderly are much more severely affected by Covid-19.  

Hayday points to an experiment conducted in 2011, which involved exposing mice to a version of the virus that causes Sars. Previous research had shown that the virus – which is also a coronavirus and a close relative of Covid-19 – triggered the production of T cells, which were responsible for clearing the infection.

The follow-up study produced similar results, but the twist was that this time the mice were allowed to grow old. As they did so, their T cell responses became significantly weaker.

However, in the same experiment, the scientists also exposed mice to a flu virus. And in contrast to those infected with Covid-19, these mice managed to hold onto their T cells that acted against influenza well into their twilight years.

“It’s an attractive observation, in the sense that it could explain why older individuals are more susceptible to Covid-19,” says Hayday. “When you reach your 30s, you begin to really shrink your thymus [a gland located behind your sternum and between your lungs, which plays an important role in the development of immune cells] and your daily production of T cells is massively diminished.”

What does this mean for long-term immunity?

“With the original Sars virus [which emerged in 2002], people went back to patients and definitely found evidence for T cells some years after they these individuals were infected,” says Hayday. “This is again consistent with the idea that these individuals carried protective T cells, long after they had recovered.”

The fact that coronaviruses can lead to lasting T cells is what recently inspired scientists to check old blood samples taken from people between 2015 and 2018, to see if they would contain any that can recognise Covid-19. The fact that this was indeed the case has led to suggestions that their immune systems learnt to recognise it after being encountering cold viruses with the similar surface proteins in the past.   

This raises the tantalising possibility that the reason some people experience more severe infections is that they haven’t got these hoards of T cells which can already recognise the virus. “I think it’s fair to say that the jury is still out,” says Hayday.

Unfortunately, no one has ever verified if people make T cells against any of the coronaviruses that give rise to the common cold. “To get funding to study this would have required a pretty Herculean effort,” says Hayday. Research into the common cold fell out of fashion in the 1980s, after the field stagnated and scientists began to move to other projects, such as studying HIV. Making progress since then has proved tricky, because the illness can be caused by any one of hundreds of viral strains – and many of them have the ability to evolve rapidly.   While antibodies are still important for tracking the spread of Covid-19, they might not save us in the end (Credit: Reuters)

While antibodies are still important for tracking the spread of Covid-19, they might not save us in the end (Credit: Reuters)

Will this lead to a vaccine?

If old exposures to cold viruses really are leading to milder cases of Covid-19, however, this bodes well for the development of a vaccine – since it’s proof that lingering T cells can provide significant protection, even years after they were made.

But even if this isn’t what’s happening, the involvement of T cells could still be beneficial – and the more we understand what’s going on, the better.

Hayday explains that the way vaccines are designed generally depends on the kind of immune response scientists are hoping to elicit. Some might trigger the production of antibodies – free-floating proteins which can bind to invading pathogens, and either neutralise them or tag them for another part of the immune system to deal with. Others might aim to get T cells involved, or perhaps provoke a response from other parts of the immune system.

“There really is an enormous spectrum of vaccine design,” says Hayday. He’s particularly encouraged by the fact that the virus is evidently highly visible to the immune system, even in those who are severely affected. “So if we can stop whatever it’s doing to the T cells of the patients we’ve had the privilege to work with, then we will be a lot further along in controlling the disease.”

It seems likely that we are going to be hearing a lot more about T cells in the future.

https://www.bbc.com/future/article/20200716-the-people-with-hidden-protection-from-covid-19

Viral Risk Assessment Through Deep Machine Learning of Genetic Testing

Daniel A. Brue, PhD

Abstract 

In this document, we outline the goals and purpose of General Genomics, and its methodology for providing metrics of viral disease propagation and individual susceptibility and response. We have developed a process to quantitatively define an individual’s risk during the COVID-19 pandemic, though the methods apply equally for other diseases as well. In this way, we are able to provide insights into disease propagation, population susceptibility, and personal risk to infection. With this information, we will help businesses, governments, and individuals to make better choices regarding public and personal safety. 

______________________________________
1 https://curo46.com 

Introduction 

General Genomics LLC is an endeavor to answer some of the questions regarding virus susceptibility, spread, and individual response to illnesses. The COVID-19 global pandemic is currently still in effect and likely will continue through several more months. This provides both a strong motivation and an unprecedented opportunity in studying viras dispersion and human reaction to specific virus infection. At no time in history have we had more information with which to work. Indeed, the most common comparison we use is the influenza outbreak of 1918. Today, modern technology provides a far better understanding of how COVID-19 has spread across the world and far more accurate medical tools for detecting and treating the disease. 

General Genomics has developed a process for using available data to provide risk assessments. This result is called a Risk Under Normalcy (RUN) score. 

The RUN score is a metric that gives a quantitative measure of individual risk of disease susceptibility. The RUN score is a result of multivariate factors that includes testing for genetic markers that may make one more or less inclined to infections. It has been shown that there do 2 exist genetic predispositions that affect one’s susceptibility and resilience to COVID-19 as well as other diseases. 

Data Collection 

General Genomics has developed a survey and an application interface that allows individuals or medical institutions to provide a person’s genetic information and demographic factors. Using either the app available on Google Play or the Apple Store, or through survey.curo46.com, anyone can upload their genetic information and any other factors they might supply, and they will receive a RUN score with a report of their most significant risk factors. 

Data Management 

All data collected will be stored and managed according to HIPAA compliance and user license agreements. Only data in aggregate will be shared or used for analysis, and individual identification will not be used for tracking. 

Several methodologies are available for managing COVID-19 data 3 . Initially, a simple queried database will be sufficient, but will transfer into a more reliable cloud system as need arises. 

______________________________________
2 https://www.nature.com/articles/s41467-020-16256-y
3 https://arxiv.org/abs/2005.05036 

Analytic 

Some work has been published in tracking propagation of COVID-19 based on statistical inference 45 including Johns-Hopkins6 , the CDC7 , research has shown that certain genetic markers are correlated with COVID0-19. With sufficient data, we will be able to confirm and/or refine these conclusions and will publish our findings. 

Many options already exist for machine learning and artificial intelligence (ML/AI) codes, and the methodology deployed by General Genomics will be chosen based on available data types and the specific questions to be answered. The chosen methods will be compared, weighted, and tuned based on empirical field data. 

Questions: 

Initial analysis shows which factors are most significant in answering the following questions: 
1. Which genetic markers are most significant to an individual’s risk of contracting COVID-19?
2. Which environmental factors, including workplace exposure, family interaction, and general exposure to the public, are most influential in a person’s general risk?
3. What independent factors, such as smoking, prescription medication, etc. should be considered in diagnosis and treatment plans?
4. Can we increase the accuracy of models tracking and predicting the spread of the pandemic by having a much more accurate understanding of human response and resilience? 

By identifying significant factors, the resultant RUN score is far more than just a number, but allows a person to weigh their own risks and take mitigating measures to reduce their risk. For example, we can provide a list of the most significant factors adding to someone’s risk, thereby allowing the person to make better informed choices for self protection and care. 

Expected Results: 

1. Inform an individual and their medical care provider information on the individual’s risk and primary risk factors. 

______________________________________
4 https://arxiv.org/abs/2005.05086
5 https://arxiv.org/abs/2005.04937
6 https://arxiv.org/abs/2005.05060
7 https://www.cdc.gov/coronavirus/2019-ncov/index.html 

2. Inform businesses that track RUN scores on their aggregate risk by allowing them to set policy on high or low risk customers, especially in situations of high population density and personal interaction.
3. Provide data on similar cases and which treatments have been most effective in combating the disease.
4. An assessment of how the disease spreads, including factors, but not limited to, social distancing and isolation. 

Based on results, the model will be continuously updated and refined. As new factors present themselves, we will be able to develop improved products to better inform the population, business, and the scientific medical community of the results. We will also be able to provide increasingly accurate products and services.

Paper: Do Your Genes Predispose You to COVID-19?

Individual differences in genetic makeup may explain our susceptibility to the new coronavirus and the severity of the disease it causes

By Loïc Mangin on April 30, 2020

Do Your Genes Predispose You to COVID-19?
Determining blood type in the ABO group system. Credit: Getty Images

Since the start of the COVID-19 pandemic several months ago, scientists have been puzzling over the different ways the disease manifests itself. They range from cases with no symptoms at all to severe ones that involve acute respiratory distress syndrome, which can be fatal. What accounts for this variability? Might the answer lie in our genes?

Coronaviruses have raised such questions for more than 15 years. In researching the 2003 outbreak of severe acute respiratory syndrome (SARS), Ralph Baric and his colleagues at the University of North Carolina at Chapel Hill identified a gene that, when silenced by a mutation, makes mice highly susceptible to SARS-CoV, the coronavirus that causes the disease. Called TICAM2, the gene codes for a protein that helps activate a family of receptors, called toll-like receptors (TLRs), that are involved in innate immunity, the first line of defense against pathogens.

Attention has now shifted to SARS-CoV-2, the new coronavirus that causes COVID-19. And TLRs have once again drawn researchers’ interest—this time to help explain the excess number of men who suffer from severe infections.

Men made up 73 percent of severe cases of COVID-19 in intensive care in France, according to a national survey published April 23. Behavioral and hormonal differences may be partially responsible. But genes may also factor into the mix. Unlike men, women have two X chromosomes and so carry double the copies of the gene TLR7, a key detector of viral activity that helps boost immunity.

The genetics of blood groups may offer some insight into whether you are liable to be infected with the virus. In late March Peng George Wang of the Southern University of Science and Technology in China and his colleagues released the results of a preprint study—not yet peer-reviewed—that compared the distribution of blood types among 2,173 COVID-19 patients in three hospitals in the Chinese cities of Wuhan and Shenzhen with that of uninfected people in the same areas. Blood type A appears to be associated with a higher risk of contracting the virus, whereas type O offers the most protection for reasons that have yet to be determined.

<See the link below for the rest of the article>

https://www.scientificamerican.com/article/do-your-genes-predispose-you-to-covid-19/?amp=true

Koco News: Local researcher forming team to study how genetics influences severity of COVID-19

Patrina Adger Reporter

OKLAHOMA CITY —

There are so many unknowns when it comes to the COVID-19 coronavirus, one being why are so many people getting the deadly disease while others show no signs?

Daniel Brue, a local researcher with General Genomics, is forming a study on how genetics influences the severity of the virus, who is more likely to get it and why.

“We never had as much feedback on a pandemic as what we are having today,” Brue said. “We know there are certain factors that are influencing this.”

Brue is leading the research team from Oklahoma City. He said the information collected from genetic markers and family history is similar to what you’d obtain through Ancestry.com or 23and Me matching.

“We can start tracking populations that have more susceptibility to COVID-19 and, ultimately, to other diseases as well,” Brue said.

Brue and his team also will work to figure out how viral patients respond to different treatments based on their genetics.

“That helps in the individual who may become ill, and it also helps their clinician in giving and describing a better treatment,” he said.

Brue told KOCO 5 that they are hoping to get federal support to help fund the study so results can come back quicker.

https://www.koco.com/article/local-researcher-forming-team-to-study-how-genetics-influences-severity-of-covid-19/32216307

Edmond Sun: Investigator unraveling mystery of COVID-19 genetic markers and virus susceptibility

Local genome researcher Daniel Brue investigates why some people are more susceptible to COVID-19 while others are not. As an inventor and the founder of General Genomics, he has established a group of people in an attempt to find more information and correlations between genetic markers and virus susceptibility of COVID-19.

Investigator unraveling mystery of COVID-19 genetic markers and virus susceptibility

The findings could potentially reveal effective methods of treatment against the virus.

“What we do know now is that there is a significant part of the population A-symptomatic to COVID-19,” said Brue, P.h.D. “So they are carriers, but they don’t know that they’re ill.”

Brue is part of a group whose focus is to increase the effectiveness and preventiveness of treatments and illnesses by warning people to understand what they may be susceptible to, based on their genetic information.

Brue said a large population of participants in companies such as 23andMe and Ancestry.com have been receiving reports about their genetic information.

“What I would like to track is how a disease effects people of different genetic dispositions,” Brue said.

A clearer picture of genetic markers linked to disease is forming from incoming information and volunteer participants. Brue correlates the effectiveness of treatments participants have received based on their genetic bands.

COVID-19 is becoming one of the best documented cases of a pandemic, and it is Brue’s hope that the group’s findings will apply to a bigger picture, triggering further scientific research of other disease processes as well.

“What I would want people to know is we have greater capacity to understand what is happening than we have ever had before,” Brue said. “If we didn’t take advantage of learning as much as we possibly can, we would be horribly remiss in not using data that we have on hand to try to improve people’s health care, and understand on the onset, what is the most effective treatment for those who are ill.”

The three inventors of the new program combine expertise in several disciplines. Ultimately they want to save lives.

Brue has an extensive background in physics and artificial intelligence/machine learning, and medical image processing. He earned his doctorate at the University of Oklahoma. Brue said he understands how sensors work and how to get the best information from them.

“What I know very well is how to extract information from measuring apparatuses that we’re using,” he said. 

Warren Gieck, of Calgary, Alberta, is an entrepreneur and industrial engineer, with experience in software development, artificial intelligence, robotics, mechatronics, and product development. 

“Our motivation is the suffering of our friends and society around us. And just as importantly, we are dads whose kids just want to go back to school,” Gieck said. “With extensive scientific and engineering expertise, we have built solutions using similar technologies for industrial applications, and we saw how we could help solve the uncertainty around the Covid-19 virus.

“Ultimately our goal is to allow people who are low risk to get back to their lives.”

A.J. Rosenthal of Midland, Texas, has a background in multi-disciplinary engineering solutions, nuclear engineering technology, and finance. Kyrie Cameron, attorney at Patterson + Sheridan, has assisted these inventors in filing their patent applications.   

“I want to figure out a way that we can better identify what people should be looking for in their own health care,” Brue said.

The goal is provide people a better understanding of how to take care of their personal health. By understanding individual risks, individuals would be able to provide care providers a better understanding of how they should be treated should they be in poor health, Brue said. As a result, physicians would have more concrete information to work with in patient care.

Brue said one of the worst aspects of what anyone goes through when they become sick is their uncertainty. A lot of people are concerned and scared of COVID-19.

“I have lived through enough personal losses to see how much the damage is on not just the person who’s ill, but their entire family around them,” Brue said.

His goal is to reduce anxiety by educating people about disease processes.

“It’s personally important to me,” Brue said.

https://www.newsbreak.com/news/1549875006654/investigator-unraveling-mystery-of-covid-19-genetic-markers-and-virus-susceptibility

Chron: Midlander creates algorithm to predict likelihood of infection

Determination would be made using person’s genetic make-up, medical history

Caitlin Randle, MRT.com/Midland Reporter-Telegram

Updated: April 16, 2020 9:11 p.m.

A Midland data scientist and his two partners have created an algorithm that uses a person’s genetic markers and medical history to predict someone’s likelihood of becoming infected with the coronavirus and suffering complications from it.

Midlander A.J. Rosenthal and his partners, Dan Brue of Oklahoma and Warren Gieck of Alberta, Canada, filed patents this week related to the algorithm.

Rosenthal said it could use a person’s genetic make-up in combination with various factors, such as their medical history and types of exposure they’ve had (i.e. a miner exposed to coal dust), to determine someone’s risk factor and assign them a correlating score.

“We’re describing potentially where a person would fall, give them a score, and that score allows them to either start going back to the workplace because they’re not going to succumb to the disease, or they won’t even be susceptible to it,” he said.

The algorithm would use the medical histories of those who have been hospitalized with COVID-19 to determine what markers could put a person at risk, Rosenthal said. He described inputting the data from past patients as “training the algorithm.”

The goal of this project is for the information to be widely accessible, Rosenthal said. He said the algorithm could potentially be on a website where a person could enter their medical information after signing a HIPPA privacy release.

“What we’re trying to do is if people want this – and we’re hoping they do – is to make it easier for them to feel comfortable and safe going back out,” he said. “Because they’ve now been locked in their houses for weeks … they don’t know if they’re going to get sick. They don’t know if they’re even susceptible to it.”

The algorithm could also be applied to other viruses and diseases, Rosenthal said, but the trio has chosen to focus on COVID-19 because there’s an immediate need.

The project’s success is contingent on partnerships with other entities – primarily, with medical providers who would give access to the medical histories of past COVID-19 patients. HIPPA laws prevent that data from being publicly available.

Rosenthal pointed to studies linking ACE2 receptors in the lungs to COVID-19 as evidence that a person’s DNA could be used to predict their risk of being infected. Some studies have found the coronavirus uses these receptors to infiltrate cells in the body.

“When the coronavirus attaches, it has a certain type of envelope that it attaches to,” Rosenthal said. “Your receptor on your lung, a lot of the coronavirus sticks to it … and from there, it propagates an infection.”

Some health entities worldwide have advised against using ibuprofen to treat COVID-19 because it’s thought to increase the number of ACE2 receptors in the body, but there’s no clear consensus among the scientific community about whether more of these receptors create a higher risk of contracting or having complications from the coronavirus.

Rosenthal said the algorithm could determine if certain combinations of medications and genetics were frequently present in those infected with the virus and serve as a guide to those with similar DNA who are also on those medications.

A former multi-disciplinary engineer in the U.S. Navy and at General Electric, Rosenthal currently works for an oil and gas company in Midland. He said he and his partners, who met working at GE, were inspired to take up this enterprise by their kids, who want to “go back to school and go to the mall and play baseball.”

“We’re just three dads. We just want our kids to have a normal life again,” Rosenthal said.

“Maybe these three dads can help the world,” he said. “The only thing we’ve got left to lose are our jobs or the economy.”

https://www.chron.com/news/article/Midlander-creates-algorithm-to-predict-likelihood-15206787.php

Midland Reporter: Midlander creates algorithm to predict likelihood of infection

Determination would be made using person’s genetic make-up, medical history

By Caitlin Randle, MRT.com/Midland Reporter-Telegram Published 9:11 pm CDT, Thursday, April 16, 2020

A Midland data scientist and his two partners have created an algorithm that uses a person’s genetic markers and medical history to predict someone’s likelihood of becoming infected with the coronavirus and suffering complications from it.

Midlander A.J. Rosenthal and his partners, Dan Brue of Oklahoma and Warren Gieck of Alberta, Canada, filed patents this week related to the algorithm.

Rosenthal said it could use a person’s genetic make-up in combination with various factors, such as their medical history and types of exposure they’ve had (i.e. a miner exposed to coal dust), to determine someone’s risk factor and assign them a correlating score.

“We’re describing potentially where a person would fall, give them a score, and that score allows them to either start going back to the workplace because they’re not going to succumb to the disease, or they won’t even be susceptible to it,” he said.

The algorithm would use the medical histories of those who have been hospitalized with COVID-19 to determine what markers could put a person at risk, Rosenthal said. He described inputting the data from past patients as “training the algorithm.”

The goal of this project is for the information to be widely accessible, Rosenthal said. He said the algorithm could potentially be on a website where a person could enter their medical information after signing a HIPPA privacy release.

“What we’re trying to do is if people want this – and we’re hoping they do – is to make it easier for them to feel comfortable and safe going back out,” he said. “Because they’ve now been locked in their houses for weeks … they don’t know if they’re going to get sick. They don’t know if they’re even susceptible to it.”

The algorithm could also be applied to other viruses and diseases, Rosenthal said, but the trio has chosen to focus on COVID-19 because there’s an immediate need.

The project’s success is contingent on partnerships with other entities – primarily, with medical providers who would give access to the medical histories of past COVID-19 patients. HIPPA laws prevent that data from being publicly available.

Rosenthal pointed to studies linking ACE2 receptors in the lungs to COVID-19 as evidence that a person’s DNA could be used to predict their risk of being infected. Some studies have found the coronavirus uses these receptors to infiltrate cells in the body.

“When the coronavirus attaches, it has a certain type of envelope that it attaches to,” Rosenthal said. “Your receptor on your lung, a lot of the coronavirus sticks to it … and from there, it propagates an infection.”

Some health entities worldwide have advised against using ibuprofen to treat COVID-19 because it’s thought to increase the number of ACE2 receptors in the body, but there’s no clear consensus among the scientific community about whether more of these receptors create a higher risk of contracting or having complications from the coronavirus.

Rosenthal said the algorithm could determine if certain combinations of medications and genetics were frequently present in those infected with the virus and serve as a guide to those with similar DNA who are also on those medications.

A former multi-disciplinary engineer in the U.S. Navy and at General Electric, Rosenthal currently works for an oil and gas company in Midland. He said he and his partners, who met working at GE, were inspired to take up this enterprise by their kids, who want to “go back to school and go to the mall and play baseball.”

“We’re just three dads. We just want our kids to have a normal life again,” Rosenthal said.

“Maybe these three dads can help the world,” he said. “The only thing we’ve got left to lose are our jobs or the economy.”

https://www.mrt.com/news/article/Midlander-creates-algorithm-to-predict-likelihood-15206787.php#photo-19218466